Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANS011
MIFTS: 55

Anus Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anus Cancer

About this section

MalaCards integrated aliases for Anus Cancer:

Name: Anus Cancer 12 15
Anal Cancer 12 20 42
Malignant Neoplasm of Anus 70
Malignant Anal Tumor 12
Cancer of the Anus 20
Anus Neoplasms 70
Anal Carcinoma 70

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:14110
ICD9CM 34 154.2 154.3
NCIt 50 C7379
SNOMED-CT 67 93669004 93676009
ICD10 32 C21.0 C21.1
UMLS 70 C0003463 C0153445 C0153446 more
Sources

Summaries for Anus Cancer

About this section
GARD : 20 Anal cancer is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the anus. Signs and symptoms of the condition include rectal bleeding ; a lump in or near the anus; anal pain; itching; changes in bowel habits; and/or swollen lymph nodes. In most cases, the underlying cause of anal cancer is unknown. There appears to be a link between anal cancer and the human papillomavirus (HPV) infection. Other risk factors for anal cancer include HIV infection, sexual activity, smoking, and a weakened immune system. The best treatment options for anal cancer depend on many factors including the stage of the condition, the location of the tumor and if there are associated conditions (i.e. HIV) but may include surgery, chemotherapy, and radiation therapy.

MalaCards based summary : Anus Cancer, also known as anal cancer, is related to human papillomavirus infectious disease and anal canal carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Anus Cancer is CD4 (CD4 Molecule), and among its related pathways/superpathways are Class I MHC mediated antigen processing and presentation and PI3K-Akt signaling pathway. The drugs Octreotide and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include anus, lung and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A large intestine cancer that is located in the anus.

MedlinePlus : 42 The anus is where stool leaves your body when you go to the bathroom. It is made up of your outer layers of skin and the end of your large intestine. Anal cancer is a disease in which cancer cells form in the tissues of the anus. Anal cancer is rare. It is more common in smokers and people over 50. You are also at higher risk if you have HPV, have anal sex, or have many sexual partners. Symptoms include bleeding, pain, or lumps in the anal area. Anal itching and discharge can also be signs of anal cancer. Doctors use tests that examine the anus to diagnose anal cancer. They include a physical exam, endoscopy, ultrasound, and biopsy. Treatments include radiation therapy, chemotherapy, and surgery. NIH: National Cancer Institute

Wikipedia : 73 Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract.... more...

Sources

Related Diseases for Anus Cancer

About this section

Diseases related to Anus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 492)
# Related Disease Score Top Affiliating Genes
1 human papillomavirus infectious disease 32.1 TP53 CDKN2A
2 anal canal carcinoma 32.0 KRT7 CDKN2A CAGE1
3 anal squamous cell carcinoma 31.5 TP53 RITA1 PIK3CA CDKN2A
4 squamous cell papilloma 31.2 TP53 HRAS GP5 CDKN2A
5 squamous cell carcinoma 30.8 TP53 PIK3CA KRT7 HRAS EGFR CDKN2A
6 cervix uteri carcinoma in situ 30.6 TP53 GP6 GP5 CDKN2A
7 papilloma 30.6 UBE3A TP53 KRT7 KRAS EGFR CDKN2A
8 cervical cancer 30.5 UBE3A TP53 PIK3CA HRAS CDKN2A
9 verrucous carcinoma 30.3 TP53 EGFR CDKN2A
10 in situ carcinoma 30.3 TP53 PIK3CA HRAS H2AC18 EGFR CDKN2A
11 basaloid squamous cell carcinoma 30.2 TP53 KRT7 EGFR CDKN2A
12 suppressor of tumorigenicity 3 30.2 UBE3A TP53 CDKN2A
13 lymphoma, non-hodgkin, familial 30.2 TP53 PIK3CA H2AC18 CD8A CD4
14 adenocarcinoma 30.2 TP53 PIK3CA KRT7 KRAS HRAS EGFR
15 appendix adenocarcinoma 30.0 KRT7 KRAS HRAS
16 mucinous adenocarcinoma 30.0 TP53 KRT7 KRAS EGFR CDKN2A
17 anogenital venereal wart 30.0 UBE3A TP53 H2AC18 GP6 GP5 CDKN2A
18 vaginal cancer 29.9 UBE3A TP53 KRT7 GP5 CDKN2A CD4
19 transitional cell carcinoma 29.8 TP53 KRT7 HRAS EGFR CDKN2A
20 basal cell carcinoma 29.7 TP53 KRT7 EGFR CDKN2A CD274
21 squamous cell carcinoma, head and neck 29.7 TP53 PIK3CA HRAS H2AC18 EGFR CDKN2A
22 peripheral nervous system disease 29.6 TP53 HRAS H2AC18 EGFR CDKN2A CD8A
23 exanthem 29.5 KRAS HRAS H2AC18 EGFR CD8A CD4
24 adenosquamous carcinoma 29.4 TP53 PIK3CA KRT7 KRAS EGFR CDKN2A
25 penile cancer 29.4 TP53 PIK3CA KRAS HRAS GP5 EGFR
26 rectum adenocarcinoma 29.4 TP53 PIK3CA KRT7 KRAS HRAS EGFR
27 vulva cancer 29.3 TP53 PIK3CA KRT7 HRAS GP5 EGFR
28 oropharynx cancer 29.0 UBE3A TP53 PIK3CA KRT7 HRAS H2AC18
29 hemorrhoid 11.0
30 anal canal squamous cell carcinoma 10.5
31 anal carcinoma in situ 10.5 TP53 CD4
32 cork-handlers' disease 10.5 CD8A CD4
33 necrotic uveal melanoma 10.5 CD8A CD4
34 early yaws 10.5 CD8A CD4
35 vulvar intraepithelial neoplasia 10.5 TP53 CDKN2A
36 ventilation pneumonitis 10.4 CD8A CD4
37 malignant peritoneal mesothelioma 10.4 EGFR CDKN2A
38 rectum cancer 10.4
39 diffuse infiltrative lymphocytosis syndrome 10.4 CD8A CD4
40 epstein-barr virus-associated gastric carcinoma 10.4 CDKN2A CD274
41 latent syphilis 10.4 CD8A CD4
42 primary cutaneous diffuse large b-cell lymphoma, leg type 10.4 CDKN2A CD274
43 type 1 diabetes mellitus 23 10.4 CD8A CD4
44 autoimmune lymphoproliferative syndrome, type iia 10.4 CD8A CD4
45 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
46 hepatic flexure cancer 10.4 KRAS HRAS
47 ovarian clear cell adenofibroma 10.4 PIK3CA KRAS
48 esophagus verrucous carcinoma 10.4 TP53 EGFR CDKN2A
49 neurofibroma 10.4 TP53 EGFR CDKN2A
50 inverted follicular keratosis 10.4 GP6 GP5

Comorbidity relations with Anus Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia

Graphical network of the top 20 diseases related to Anus Cancer:



Diseases related to Anus Cancer
Sources

Symptoms & Phenotypes for Anus Cancer

About this section

UMLS symptoms related to Anus Cancer:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; pruritus ani; gastrointestinal gas

GenomeRNAi Phenotypes related to Anus Cancer according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.01 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.01 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.01 KRAS
4 Decreased viability GR00106-A-0 10.01 KRAS
5 Decreased viability GR00221-A-1 10.01 CDKN2A EGFR HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.01 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.01 CDKN2A HRAS
8 Decreased viability GR00221-A-4 10.01 CDKN2A EGFR PIK3CA
9 Decreased viability GR00301-A 10.01 KRAS
10 Decreased viability GR00381-A-1 10.01 KRAS
11 Decreased viability GR00402-S-2 10.01 PIK3CA

MGI Mouse Phenotypes related to Anus Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.7 CD274 CD4 CD8A CDKN2A EGFR GP6
2 no phenotypic analysis MP:0003012 9.28 CD274 CD4 CDKN2A EGFR HRAS KRAS
Sources

Drugs & Therapeutics for Anus Cancer

About this section

Drugs for Anus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
2
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
3
Pembrolizumab Approved Phase 3 1374853-91-4
4
nivolumab Approved Phase 3 946414-94-4
5
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
6
Ipilimumab Approved Phase 3 477202-00-9
7
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
8
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
9 Gastrointestinal Agents Phase 3
10 Antineoplastic Agents, Hormonal Phase 3
11 Antineoplastic Agents, Immunological Phase 3
12 Adjuvants, Immunologic Phase 3
13 Anesthetics Phase 3
14 Antibiotics, Antitubercular Phase 2, Phase 3
15 Mitomycins Phase 2, Phase 3
16 Antimetabolites Phase 2, Phase 3
17 Anti-Bacterial Agents Phase 2, Phase 3
18
Cidofovir Approved Phase 2 113852-37-2 60613
19
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
20
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
21
Durvalumab Approved, Investigational Phase 2 1428935-60-7
22
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
23
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2 149436
24
leucovorin Approved Phase 1, Phase 2 58-05-9 6006
25
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
26
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
27
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
28
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
29
Panitumumab Approved, Investigational Phase 1, Phase 2 339177-26-3 50070211
30
Pomalidomide Approved Phase 2 19171-19-8
31
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
32
Edetic Acid Approved, Vet_approved Phase 2 60-00-4, 62-33-9 6049
33
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
34
Pentetic acid Approved Phase 2 67-43-6
35
Palonosetron Approved, Investigational Phase 2 135729-56-5, 119904-90-4 148211
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Manganese Approved, Nutraceutical Phase 1, Phase 2 7439-96-5 27854
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
39 Immunologic Factors Phase 1, Phase 2
40 Psychotropic Drugs Phase 2
41 Anticonvulsants Phase 2
42 Interleukin-12 Phase 1, Phase 2
43 Immunoglobulins Phase 2
44 Antibodies Phase 2
45 Trace Elements Phase 1, Phase 2
46 Nutrients Phase 1, Phase 2
47 Micronutrients Phase 1, Phase 2
48 Protective Agents Phase 1, Phase 2
49 Antidotes Phase 1, Phase 2
50 Vitamin B9 Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Unknown status NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
2 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
3 Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer Completed NCT00025090 Phase 3 cisplatin;fluorouracil;mitomycin C
4 A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
5 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
6 Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study Completed NCT00003652 Phase 3 cisplatin;fluorouracil
7 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
8 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
9 A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients Recruiting NCT04444921 Phase 3 Carboplatin;Paclitaxel
10 A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Recruiting NCT03233711 Phase 3
11 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
12 A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. Recruiting NCT04635423 Phase 3
13 Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
14 Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
15 Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Unknown status NCT03381352 Phase 2 Capecitabine;Mitomycin C
16 An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
17 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Unknown status NCT03302858 Phase 2
18 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
19 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
20 A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals Completed NCT00052897 Phase 1, Phase 2
21 Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma Completed NCT00324415 Phase 2 cisplatin;fluorouracil
22 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women Completed NCT00550589 Phase 2 cidofovir
23 A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
24 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
25 Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal Completed NCT02399813 Phase 2 ADXS11-001
26 Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
27 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
28 Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging Completed NCT01717391 Phase 2 fluorothymidine F 18
29 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
30 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
31 Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. Recruiting NCT04230759 Phase 2 Chemotherapy;Durvalumab
32 A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
33 A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer Recruiting NCT03018418 Phase 2 Chemotherapy
34 A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001 Recruiting NCT03386500 Phase 1, Phase 2 BMX-001
35 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
36 A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer Recruiting NCT02919969 Phase 2 Pembrolizumab
37 Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Recruiting NCT04287868 Phase 1, Phase 2
38 A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) Recruiting NCT04166318 Phase 2 Capecitabine;Fluorouracil;Mitomycin
39 Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects With HPV Positive Cancers Recruiting NCT04432597 Phase 1, Phase 2
40 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
41 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
42 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
43 Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
44 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
45 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons Recruiting NCT02437851 Phase 2
46 Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma Recruiting NCT04357873 Phase 2 pembrolizumab; vorinostat
47 A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib
48 Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
49 A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients Active, not recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
50 Randomized Phase 2 Trial of Cetuximab and Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment Active, not recruiting NCT03944252 Phase 2 Avelumab;Cetuximab

Search NIH Clinical Center for Anus Cancer

Sources

Genetic Tests for Anus Cancer

About this section
Sources

Anatomical Context for Anus Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Anus Cancer:

19
Anus

MalaCards organs/tissues related to Anus Cancer:

40
Lung, Breast, Lymph Node, Skin, Colon, Cervix, Bone
Sources

Publications for Anus Cancer

About this section

Articles related to Anus Cancer:

(show top 50) (show all 2272)
# Title Authors PMID Year
1
High-Resolution Anoscopy Surveillance After Anal Squamous Cell Carcinoma: High-Grade Squamous Intraepithelial Lesion Detection and Treatment May Influence Local Recurrence. 42 61
32969879 2020
2
Perianal and perineal rhabdomyosarcomas: a retrospective multicenter study of 35 cases. 42
33516222 2021
3
Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years. 42
33498165 2021
4
Incidence of human papillomavirus-related anogenital precancer and cancer in women with diabetes: A nationwide registry-based cohort study. 61
33129233 2021
5
Anal cancer screening and prevention: A review for dermatologists. 61
33797819 2021
6
Anal cancer and precancerous lesions: a call for improvement. 61
33714370 2021
7
Knowledge, Attitudes, and Experiences of Anal Cancer and Anal Cancer Screening Among a Clinical Sample of Hispanic Women. 61
33660677 2021
8
High-risk human papillomavirus test in anal smears: can it optimize the screening for anal cancer? 61
33306557 2021
9
Clinical Practice Guideline: Anal Cancer—Diagnosis, Treatment and Follow-up 61
33531112 2021
10
An Assessment of Cancer Education Needs to Promote Mid-Adult HPV Vaccination Among Male Sexual Minorities. 61
31707641 2021
11
Predicting outcomes in anal cancer patients using multi-centre data and distributed learning - a proof-of-concept study. 61
33753156 2021
12
Evolution of the Role of Radiotherapy for Anal Cancer. 61
33801992 2021
13
Optimal Radiotherapy Dose in Anal Cancer: Trends in Prescription Dose and Association with Survival. 61
32152823 2021
14
Anal cancer survival: a socioeconomic analysis. 61
33645271 2021
15
[Summary and comments on the S3 guideline on anal cancer: diagnostics, treatment and aftercare of anal canal and margin cancers]. 61
33598717 2021
16
Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. 61
33270909 2021
17
Pelvic exenteration for colorectal and non-colorectal cancer: a comparison of perioperative and oncological outcome. 61
33677655 2021
18
Are colorectal cancer patients at risk for COVID-19 infection during the postoperative period? The Covid-GRECCAR study. 61
33495872 2021
19
Screening Women for Anal Cancers: Guidance for Health Care Professionals. 61
33606380 2021
20
The impact of gender and HPV status on anal squamous cell carcinoma survival. 61
33787999 2021
21
The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men. 61
32342984 2021
22
Sexual behaviours associated with incident high-risk anal human papillomavirus among gay and bisexual men. 61
33727339 2021
23
Myocardial Ischemia Induced by 5-Fluorouracil: A Prospective Electrocardiographic and Cardiac Biomarker Study. 61
32959474 2021
24
Low human papillomavirus (HPV) vaccine uptake among men living with human immunodeficiency virus (HIV): Cross-sectional findings from a clinical cohort. 61
33221269 2021
25
Wide posterior gluteal-thigh propeller flap for reconstruction of perineal defects. 61
33030284 2021
26
The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation. 61
33562397 2021
27
Association of Human Papillomavirus Genotype 16 Lineages With Anal Cancer Histologies Among African Americans. 61
33075347 2021
28
Anal cancer screening among women with HIV: provider experiences and system-level challenges. 61
33594934 2021
29
Hellenic society of medical oncology (HESMO) guidelines for the management of anal cancer. 61
33231836 2021
30
Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer. 61
33545256 2021
31
DNA methylation markers have universal prognostic value for anal cancer risk in HIV-negative and HIV-positive individuals. 61
33580586 2021
32
Cytology-based screening for anal intraepithelial neoplasia in women with a history of cervical intraepithelial neoplasia or cancer. 61
33002327 2021
33
A 12-year retrospective evaluation of anal pre-cancerous lesions and cancer in people living with HIV-1 infection in the Southeastern U.S. 61
33596943 2021
34
State of the art treatment for stage I to III anal squamous cell carcinoma: A systematic review and meta-analysis. 61
33549645 2021
35
Feasibility and safety study of a high resolution wide field-of-view scanning endoscope for circumferential intraluminal intestinal imaging. 61
33574405 2021
36
HPV genotyping and risk factors for anal high-risk HPV infection in men who have sex with men from Toronto, Canada. 61
33637798 2021
37
Exploiting the Microbiota for the Diagnosis of Anal Precancerous Lesions in Men Who Have Sex With Men. 61
33544868 2021
38
Correlation of anal cytology with follow-up histology and Human Papillomavirus genotyping: A 10-year experience from an academic medical center. 61
33310590 2021
39
Multidisciplinary management of anal intraepithelial neoplasia and rate of progression to cancer: A retrospective cohort study. 61
32873453 2021
40
Comparing Anal Cancer Screening Algorithms Using Cytology and HPV DNA Testing in Three High-risk Populations. 61
33388757 2021
41
Anal Cancer and Anal Cancer Screening Knowledge, Attitudes, and Perceived Risk Among Women Living With HIV. 61
33149011 2021
42
Measuring importance of outcomes to patients: a cross-sectional survey for the German anal cancer guideline. 61
32987160 2021
43
Salvage surgery for locally recurrent anal cancer after intensity modulated radiation therapy with concurrent chemotherapy. 61
33360327 2021
44
Use of advanced PET-volume metrics predicts risk of local recurrence and overall survival in anal cancer. 61
33539412 2021
45
Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. 61
33261895 2021
46
Factors predicting severity level, progression and recurrence risk of acute left colonic diverticulitis in Turkey: A multicenter study. 61
33394481 2021
47
The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD. 61
32080713 2021
48
Longitudinal Analysis of Mental Disorder Burden Among Elderly Patients With Gastrointestinal Malignancies. 61
33401234 2021
49
Tailoring the radiotherapy approach in patients with anal squamous cell carcinoma based on inguinal sentinel lymph node biopsy. 61
32964456 2021
50
Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy. 61
33723132 2021
Sources

Variations for Anus Cancer

About this section
Sources

Expression for Anus Cancer

About this section
Search GEO for disease gene expression data for Anus Cancer.
Sources

Pathways for Anus Cancer

About this section

Pathways related to Anus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.38 UBE3A TP53 PIK3CA KRAS HRAS EGFR
2
PI3K-Akt signaling pathway 36
Show member pathways
 13 UBE3A TP53 PIK3CA KRAS HRAS EGFR
3
Human cytomegalovirus infection 36
Show member pathways
 12.84 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
4
Pathways in cancer 36
12.83 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
5
Endometrial cancer 36
Show member pathways
 12.76 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
6
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.74 TP53 PIK3CA KRAS HRAS EGFR
7
Apoptosis Modulation and Signaling 1
Show member pathways
 12.72 TP53 PIK3CA KRAS HRAS CDKN2A
8
Gastric cancer 36
Show member pathways
 12.71 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
9
PKC-Theta Pathway 63
Show member pathways
 12.69 TP53 KRAS HRAS CD8A CD4
10
4-1BB Pathway 63
Show member pathways
 12.67 TP53 KRAS HRAS EGFR CD4
11
Glioma 36
Show member pathways
 12.6 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
12
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.51 TP53 PIK3CA KRAS HRAS EGFR
13
ErbB signaling pathway 36 1
Show member pathways
 12.5 TP53 PIK3CA KRAS HRAS EGFR
14
Immune response IL-23 signaling pathway 23
Show member pathways
 12.49 TP53 PIK3CA KRAS HRAS EGFR CD4
15
Phospholipase D signaling pathway 36
Show member pathways
 12.42 PIK3CA KRAS HRAS EGFR
16
Apoptosis Pathway 69
Show member pathways
 12.4 TP53 PIK3CA KRAS HRAS EGFR
17
MicroRNAs in cancer 36
12.4 TP53 PIK3CA KRAS HRAS EGFR CDKN2A
18
VEGF Signaling 66
Show member pathways
 12.37 TP53 KRAS HRAS EGFR
19
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.33 TP53 PIK3CA HRAS EGFR
20
Signaling by ERBB2 65
Show member pathways
 12.33 PIK3CA KRAS HRAS EGFR
21
Development EGFR signaling pathway 23
Show member pathways
 12.32 PIK3CA KRAS HRAS EGFR
22
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.31 TP53 KRAS HRAS EGFR
23
Inflammatory mediator regulation of TRP channels 36
Show member pathways
 12.28 PIK3CA KRAS HRAS EGFR
24
Proteoglycans in cancer 36
12.25 TP53 PIK3CA KRAS HRAS EGFR
25
Cell surface interactions at the vascular wall 65
Show member pathways
 12.24 PIK3CA KRAS HRAS GP6
26
T cell receptor signaling pathway 36
Show member pathways
 12.24 PIK3CA KRAS HRAS EGFR CD8A CD4
27
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.23 TP53 PIK3CA KRAS HRAS EGFR
28
mTOR Pathway 69
Show member pathways
 12.18 TP53 PIK3CA KRAS HRAS
29
Longevity regulating pathway 36
Show member pathways
 12.14 TP53 PIK3CA KRAS HRAS
30
Development EGFR signaling via small GTPases 23
Show member pathways
 12.14 PIK3CA KRAS HRAS EGFR
31
Human T-cell leukemia virus 1 infection 36
12.14 TP53 PIK3CA KRAS HRAS CDKN2A CD4
32
Estrogen signaling pathway (KEGG) 36
12.1 PIK3CA KRAS HRAS EGFR
33
FoxO signaling pathway 36
Show member pathways
 12.09 PIK3CA KRAS HRAS EGFR
34
UVA-Induced MAPK Signaling 63
Show member pathways
 12.08 TP53 KRAS HRAS EGFR
35
Cellular senescence (KEGG) 36
12.05 TP53 PIK3CA KRAS HRAS CDKN2A
36
Viral carcinogenesis 36
12.04 UBE3A TP53 PIK3CA KRAS HRAS CDKN2A
37
Thyroid hormone signaling pathway 36
12.02 TP53 PIK3CA KRAS HRAS
38
Sphingolipid signaling pathway 36
12 TP53 PIK3CA KRAS HRAS
39
Signaling by ERBB4 65
Show member pathways
 11.93 PIK3CA KRAS HRAS EGFR
40
DNA Damage Response (only ATM dependent) 1
11.86 TP53 PIK3CA KRAS HRAS CDKN2A
41
VEGF Pathway (Tocris) 69
Show member pathways
 11.83 PIK3CA KRAS HRAS
42
Signaling by Ligand-Responsive EGFR Variants in Cancer 65
Show member pathways
 11.82 PIK3CA KRAS HRAS EGFR
43
Glioblastoma Multiforme 63
11.81 TP53 KRAS HRAS EGFR CDKN2A
44
Platinum drug resistance 36
11.77 TP53 PIK3CA CDKN2A
45
Commom Cytokine Receptor G Chain Siganaling Pathway 66
11.76 PIK3CA KRAS HRAS
46
TGF-beta Signaling Pathway (sino) 66
11.74 PIK3CA KRAS HRAS
47
Renal cell carcinoma 36
11.74 PIK3CA KRAS HRAS
48
Mitophagy - animal 36
11.73 TP53 KRAS HRAS
49
Acute myeloid leukemia 36
11.72 PIK3CA KRAS HRAS
50
Pathways Affected in Adenoid Cystic Carcinoma 1
11.71 TP53 PIK3CA HRAS
Sources

GO Terms for Anus Cancer

About this section

Biological processes related to Anus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.62 KRAS HRAS EGFR CD4
2 cell surface receptor signaling pathway GO:0007166 9.55 HRAS EGFR CD8A CD4 CD274
3 positive regulation of MAP kinase activity GO:0043406 9.43 KRAS HRAS EGFR
4 response to isolation stress GO:0035900 9.4 KRAS HRAS
5 enzyme linked receptor protein signaling pathway GO:0007167 9.37 GP6 CD4
6 liver development GO:0001889 9.26 PIK3CA KRAS HRAS EGFR
7 Ras protein signal transduction GO:0007265 8.92 TP53 KRAS HRAS CDKN2A

Molecular functions related to Anus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A
Sources

Sources for Anus Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....